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ABSTRACT
Objective To assess the cost effectiveness of including
preadolescent boys in a routine human papillomavirus
(HPV) vaccination programme for preadolescent girls.
Design Cost effectiveness analysis from the societal
perspective.
Setting United States.
Population Girls and boys aged 12 years.
Interventions HPV vaccination of girls alone and of girls
and boys in the context of screening for cervical cancer.
Main outcome measure Incremental cost effectiveness
ratios, expressed as cost per quality adjusted life year
(QALY) gained.
Results With 75% vaccination coverage and an
assumptionofcomplete,lifelongvaccineefficacy,routine
HPV vaccination of 12 year old girls was consistently less
than $50000 per QALY gained compared with screening
alone. Including preadolescent boys in a routine
vaccinationprogrammeforpreadolescentgirlsresultedin
higher costs and benefits and generally had cost
effectiveness ratios that exceeded $100000 per QALY
across a range of HPV related outcomes, scenarios for
cervical cancer screening, and assumptions of vaccine
efficacy and duration. Vaccinating both girls and boys fell
below a willingness to pay threshold of $100000 per
QALY only under scenarios of high, lifelong vaccine
efficacy against all HPV related diseases (including other
non-cervical cancers and genital warts), or scenarios of
lower efficacy with lower coverage or lower vaccine costs.
Conclusions Given currently available information,
including boys in an HPV vaccination programme
generally exceeds conventional thresholds of good value
for money, even under favourable conditions of vaccine
protection and health benefits. Uncertainty still exists in
many areas that can either strengthen or attenuate our
findings. As new information emerges, assumptions and
analyses will need to be iteratively revised to continue to
inform policies for HPV vaccination.
INTRODUCTION
Persistent infection with high risk oncogenic types of
humanpapillomavirus(HPV)hasbeenestablishedasa
necessaryfactorin causingcervicalcancer. Twotypes,
HPV16andHPV18,areresponsibleforabout70%of
the cases of cervical cancer worldwide and contribute
to over 80% of anal cancers; 30% of vulvar, vaginal,
and oropharyngeal cancers; and 20% of oral
cancers.
1-3 Furthermore, two low risk non-oncogenic
types, HPV 6 and HPV 11, are associated with most
cases of anogenital warts and juvenile onset recurrent
respiratory papillomatosis, a rare yet severe respira-
tory condition.
4
Vaccines that target HPV 16 and HPV 18 have
shown high, sustained efficacy against persistent type
specific infections and precancerous cervical, vulvar,
and vaginal lesions among females without previous
exposuretotheseHPVtypes.
5-11Thequadrivalentvac-
cine also targets HPV 6 and HPV 11 and has high effi-
cacy against incident genital warts among females.
5
Because the vaccine is most efficacious before expo-
sure to HPV, current guidelines prioritise girls aged
11 to 12 as the primary target group for HPV vaccina-
tion; previous cost effectiveness analyses have consis-
tentlyreportedthatHPV vaccinationof preadolescent
girls provides good value for money.
12-22 Opinions on
the optimal age limit for a catch-up vaccination pro-
gramme in girls are more varied, extending to age 18
or 26 in the United States.
2324
Recent data on the use of the HPV vaccine in males
suggest high efficacy against vaccine type infections
and external genital lesions.
2526 Despite limited data,
the HPV vaccine is licensed and recommended for
boys in several countries. In the US, the Food and
Drug Administration has not yet approved the HPV
vaccine for boys but is expected to consider it in the
near future; agencies responsible for guidelines, such
as the Advisory Committee on Immunization Prac-
tices and the American Cancer Society, will need to
advise whether or not HPV vaccination should be
recommended for boys. Because HPV is a sexually
transmitted infection, vaccinating boys may lead not
only to direct health benefits (for themselves) but also
toindirecthealthbenefits(forsexualpartners)through
reduced transmission of HPV. To assess the value of
adding boys to an HPV vaccination programme, both
theincrementalhealthbenefitsthatmayaccruetomen
and women and the economic costs of the programme
should be compared with those associated with vacci-
nating girls alone. In particular in the US, as discus-
sions about health reform proceed, there has been a
call for analyses to compare the value of different
health interventions.
2728
Harvard School of Public Health,
Department of Health Policy and
Management, Center for Health
Decision Science, 718 Huntington
Avenue, Boston, MA 02115, USA
Correspondence to: J J Kim
jkim@hsph.harvard.edu
Cite this as: BMJ 2009;339:b3884
doi:10.1136/bmj.b3884
BMJ | ONLINE FIRST | bmj.com page 1 of 10The most important health benefits from HPV vac-
cination of adolescents (that is, the prevention of can-
cer) will not be observed for years, possibly decades.
Disease simulation models that are calibrated to fit
empirical data can be used within a decision analytical
framework to synthesise the best available data, com-
parethehealthandeconomicoutcomesofusingdiffer-
ent interventions, and explore “what if” scenarios that
wouldotherwisebeinfeasibleorunethicaltopursuein
a clinical study. We adopted such a framework to
assessthecost effectivenessofincludingpreadolescent
boysinanHPVvaccinationprogrammeforpreadoles-
cent girls in the US.
METHODS
We used a series of published disease simulation mod-
els that synthesise epidemiological, clinical, and eco-
nomic data to evaluate the incremental benefits and
cost effectiveness of including preadolescent (age
12 years) boys in a routine HPV vaccination pro-
gramme for preadolescent girls in the context of
screening for cervical cancer in the US. The primary
analysis included outcomes related to cervical disease,
as well as other cancers associated with HPV 16 and
HPV 18 for both women and men, which are relevant
tobothbivalentandquadrivalentvaccines.Secondary
analyses included HPV 6 and HPV 11 associated gen-
ital warts as well as HPV 6 and HPV 11 associated
juvenile onset recurrent respiratory papillomatosis.
Weassessedtheimpactofuncertaintiessuchasvaccine
efficacy in boys, the long term impact on health out-
comesnotyetobservedinclinicaltrials(anal,oral,and
oropharyngeal cancers and juvenile onset recurrent
respiratory papillomatosis), achievable vaccination
coverage, duration of vaccine protection, and cross
protective effects against high risk HPV infections
and cervical disease other than those related to HPV
16 and HPV 18. In sensitivity analysis we assessed the
influence of additional uncertain variables, such as
costs associated with screening and vaccination.
As recommended for economic evaluations of pub-
lichealthinterventionsinthe US
29 weadopteda socie-
talperspective,includingcostsregardlessofthepayor,
and discounted costs and health benefits by 3%
annually.Wecalculatedincrementalcosteffectiveness
ratiosforeachstrategyastheadditionalcostdividedby
the additional health benefit associated with one strat-
egy compared with the next less costly strategy. We
eliminated those strategies that were more costly and
lesseffective (thatis,stronglydominated)or lesscostly
and less cost effective (that is, weakly dominated) than
analternativestrategy.Althoughthereisnoconsensus
on a cut-off point for good value for resources, we pre-
sent our results in the context of commonly cited
thresholds per quality adjusted life year (QALY) of $
50000 and $100000.
30
Models
We used a dynamic transmission model to simulate
sexual transmission of HPV 16 and HPV 18 infections
between women and men and an individual based
microsimulation model to reflect HPV induced cervi-
cal diseasein women,bothofwhich were calibratedto
fit to epidemiological data. We used incidence based
models to estimate the health and economic burden of
non-cervical diseases for both sexes. Details of the
models have been published.
1231-33
Thedynamicmodelisanagestructured,population
based model that simulates multiple birth cohorts of
females and males from birth until death. According
to patterns of sexual behaviour in the US,
34 females
and males form heterosexual partnerships as they
age, and HPV 16 or HPV 18 may be transmitted
depending on the number of new contacts per year,
prevalence of HPV 16 and HPV 18 in the opposite
sexatanygiventime,andtheprobabilitiesoftransmit-
tingthe twotypestoanuninfectedpartner.Aftera first
infectionwithHPVandclearance,individualsdevelop
partialtypespecificnaturalimmunity,effectivelyredu-
cing their susceptibility to future infection with the
same types. Women with an HPV infection can
develop cervical intraepithelial neoplasia grade I, or
grade II or III, which may regress naturally, and
those with cervical intraepithelial neoplasia II or III
may develop invasive cancer. Death can occur in any
year from disease specific or background mortality.
The individual based stochastic model has a similar
structure but includes all HPV types (categorised as
HPV 16, HPV 18, other high risk types, and low risk
types),representstheincidenceofHPVasafunctionof
age and individual level characteristics, tracks each
individual’s history (for example, vaccination, screen-
ing,treatment,andpastabnormalities),andaccommo-
dates complex secondary prevention strategies.
123233
The dynamic model was used to estimate reductions
in age specific incidence of HPV 16 and HPV 18 with
vaccination strategies, reflecting direct benefits to
those vaccinated as well as indirect benefits to those
not vaccinated(herdimmunity). Thegeneratedreduc-
tions in incidence of HPV for females under scenarios
of vaccinating girls alone or with boys served as inputs
to the stochastic model, which we then used to com-
pare vaccination strategies in the context of screening
for cervical cancer.
Model inputs and assumptions
Initial model variables were based on epidemiological
studies, cancer registries, population surveys, and
demographic statistics from the US, where possible.
The models were calibrated using a likelihood based
approach to fit to empirical data, such as age specific
prevalence of HPV, age specific incidence of cervical
cancer, and HPV type distribution observed in the US
population.
135-40 The parameterisation, calibration,
and validation approaches have been described
elsewhere.
123132 (See web extra on bmj.com for details
relevant to the current analysis.)
For non-cervical cancer conditions, data included
incidence of other HPV associated female and male
cancers, genital warts, and juvenile onset recurrent
respiratory papillomatosis, the proportion of each dis-
easeattributabletoHPVtypestargetedbythevaccine,
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(table 1).
1-441-50 Costs (2006 prices) included direct
medical costs associated with vaccination (for exam-
ple, three doses at $120 per dose, wastage, supplies,
and administration)
51-54 and with screening, diagnosis,
and treatment (for example, tests, procedures, admis-
sions to hospital). Estimates of direct non-medical
costs, such as patient time and transportation, were
included for all interventions.
Analysis
To estimate the long term outcomes associated with
vaccination and screening strategies we projected the
lifetime health and economic consequences for all
birth cohorts in the first 10 years of the vaccination
programme, which was assumed to continue for
100years.Totallifetimecostsandhealthbenefitsasso-
ciated with each vaccination strategy served as the
basis for cost effectiveness calculations.
Strategies included HPV vaccination of 12 year old
girls alone and with 12 year old boys. Our base case
analysis was purposefully constructed to consider a
best case scenario for routine vaccination; as such, we
assumed a coverage rate of 75% for both sexes on the
basisofachievablecoverageinpastsuccessfulvaccina-
tion programmes for adolescents
5556 but also explored
theimplicationsoflowercoverage(50%).Weassumed
vaccine efficacy against incidence of vaccine targeted
HPVinfectionstobelifelongand100%amongfemales
and 85% among males without a history of those
infections
925; efficacy against disease outcomes asso-
ciated with vaccine targeted HPV types was 100% for
females and 90% for males.
5-1026 In sensitivity analyses
we relaxed favourable assumptions to provide key
insights into the influence of uncertainties on policy
results. In particular we explored an alternative sce-
nario of 75% efficacy against HPV infection and dis-
ease outcomes in boys only and waning immunity at
20years.Wealsoexploredtheimpactofvaccinecross-
protective effects against cervical disease associated
with high risk HPV types other than HPV 16 or HPV
18 (12.1% to 54.0%).
10
We evaluated the vaccination strategies in the con-
text of routine screening for cervical cancer beginning
atanaverageageof20andusingcytology(HPVDNA
testingfortriageofequivocalresults),withandwithout
a switch to combined cytology and HPV DNA testing
after age 30, based on US guidelines.
345758 Abnormal
cytology test results were managed according to
recommended clinical guidelines (see web extra).
59
Based on patterns of screening for cervical cancer
reported for US women,
60-62 we assumed that current
screening involves 53% of women being screened
annually, 17% every two years, 11% every three
years, 14% every five years, and 5% never screened.
Because future screening practice is likely to change
in response to a decreased risk of cervical disease in
the population after vaccination, we also considered
HPV vaccination alongside scenarios of less frequent
routinescreening(everytwoorthreeyears),startingat
a later age (25), with combined cytology and HPV
DNA testing for primary screening in older women
(after age 35).
63
For both bivalent and quadrivalent vaccines we esti-
mated QALYs gained and costs averted for HPV 16
and HPV 18 associated non-cervical cancers for both
sexesusingagespecificincidence,
41takingintoaccount
cancer specific mortality and quality of life weights—
that is, utilities (table 1).
1-441-50 To reflect the benefits
of the quadrivalent vaccine on HPV 6 and HPV 11,
we modelled the age specific incidence and duration
of genital warts,
43 including their impact on quality of
life and costs,
434547 and we estimated QALYs gained
and costs averted with vaccination. Similarly, we esti-
mated cases of juvenile onset recurrent respiratory
papillomatosis averted per vaccinated female using
dataonthenumberofbirthsperwoman,
64annualinci-
dence of juvenile onset recurrent respiratory papillo-
matosis per live child,
46 costs per case, and effects on
quality of life.
4749 Vaccination was assumed to fully
reducethe numberof cases that are attributable tovac-
cine targeted types; vaccine protection included both
directandindirectbenefitsestimatedfromthedynamic
model. Because of the uncertainty related to the long
term benefits of the vaccine on outcomes not yet
observed in clinical trials (other non-cervical cancers
and juvenile onset recurrent respiratory papillomato-
sis), we assessed the impact of more conservative
assumptions, such as a 50% reduction in cases attribu-
table to vaccine targeted types.
RESULTS
Under assumptions of 75% vaccination coverage and
complete, lifelong vaccine protection, routine HPV
vaccination of 12 year old girls who are screened
usingcytology(HPVDNAtestingfortriage)atcurrent
rates in adulthood was associated with an incremental
cost effectiveness ratio of $40310 per QALY gained
compared with screening alone when including only
benefits related to cervical disease (table 2). Adding
12 year old boys to the vaccination programme pro-
vided benefitsfor higher costs and had a cost effective-
ness ratio of $290290 per QALY compared with
vaccinating girls only.
When including other HPV 16 and HPV 18 related
cancers among women, the cost per QALY of vacci-
natinggirls alonedecreasedbelow$32000 and of vac-
cinating both sexes remained above $200000 under
assumptions of 50% efficacy against HPV 16 and
HPV 18 non-cervical cancers (100% efficacy against
cervical disease) or 100% efficacy against all cancers
caused by HPV 16 and HPV 18 in women. When
including cancer benefits for both sexes, the cost effec-
tiveness ratio for vaccinating boys in addition to girls
remained above $100000 per QALY.
When current screening involved a switch to com-
bined cytology and HPV DNA testing after age 30
(table 2), the cost effectiveness ratio for the strategy of
vaccinating girls alone stayed consistently below
$ 5 00 0 0p e rQ A L Ya c r o s sa l ls c e n a r i o sa n dw a sg e n e r -
ally lower (more attractive) than the corresponding
ratios in the previous analysis except when reflecting
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Health condition Women Men
Cervical cancer:
Incidence rate (per 100 000)† 4.2-62.8 —
5 year survival (%)
41‡ 16.5-92.0 —
Quality of life adjustment
45 48§ 0.48-0.76 —
Cases attributable to HPV 16 and HPV 18 (%)
1-3 70.0 —
Cost per case ($)
42¶ 26 540-45 540 —
Vulvar cancer:
Incidence rate (per 100 000) age ≥20
41 0.2-19.6 —
5 year survival (%)
41 77.8 —
Quality of life adjustment
48§ 0.68 —
Cases attributable to HPV 16 and HPV 18 (%)
23 32.0 —
Cost per case ($)
47¶ 20 430 —
Vaginal cancer:
Incidence rate (per 100 000) age ≥20
41 0.1-6.0 —
5 year survival (%)
41 55.7 —
Quality of life adjustment
48§ 0.68 —
Cases attributable to HPV 16 and HPV 18 (%)
23 32.0 —
Cost per case ($)
47¶ 23 440 —
Penile cancer:
Incidence rate (per 100 000) age ≥20
41 — 0.0-7.6
5 year survival (%)
41 — 75.0
Quality of life adjustment
48§ — 0.68
Cases attributable to HPV 16 and HPV 18 (%)
23 — 25.2
Cost per case ($)
47¶ — 17 110
Anal cancer:
Incidence rate (per 100 000) age ≥20
41 0.0-5.6 0.1-4.3
5 year survival (%)
41 66.2 64.1
Quality of life adjustment
48§ 0.68
Cases attributable to HPV 16 and HPV 18 (%)
23 82.8
Cost per case ($)
47¶ 31 300
Oral cancer:
Incidence rate (per 100 000) age ≥20
41 0.2-13.9 0.1-17.7
5 year survival (%)
41 62.6 57.6
Quality of life adjustment§ 0.68
Cases attributable to HPV 16 and HPV 18 (%)
3 24.0
Cost per case ($)
47¶ 37 370
Oropharyngeal cancer:
Incidence rate (per 100 000) age ≥20
41 0.0-1.1 0.0-2.9
5 year survival (%)
41 62.6 57.6
Quality of life adjustment§ 0.68
Cases attributable to HPV 16 and HPV 18 (%)
3 31.0
Cost per case ($)
47¶ 37 370
Genital warts:
Prevalence rate (per 1000)
43 0.07-6.20 0.13-5.01
Quality of life adjustment
43 45§ 0.91
Cases attributable to HPV 6 and HPV 11 (%)
44 4 90.0
Cost per case ($)
47¶ 430
Juvenile onset recurrent respiratory papillomatosis:
Incidence rate (per 100 000) age 0-14
46 4.30
Quality of life adjustment
49§ 0.69
Cases attributable to HPV 6 and HPV 11 (%)
4 100.0
Cost per case ($)
47¶ 62 010
*Range represents age specific values; rates are annual unless stated otherwise. Some data are not applicable to both sexes.
†Incidence of cervical cancer represents model generated projections by calibrated stochastic model in absence of screening or vaccination (natural history).
‡Five year survival for cervical cancer varied according to stage (92.0% for local, 55.7% for regional, 16.5% for distant).
41
§Quality of life adjustment assumes health state utility weight of 0 (death) to 1 (perfect health). Health state utility weight for cervical cancer varied
according to stage: 0.76 for local cancer and 0.67 for regional cancer for five years,
45 and 0.48 for distant cancer over lifetime with disease.
48 For
non-cervical cancers, average health state utility weight of 0.68 over the lifetime with disease is assumed, to reflect a weighted average of stage
specific utilities and stage distribution of disease.
48 For genital warts, health state utility weight of 0.91 over three months is assumed
43 45;f o r
juvenile onset recurrent respiratory papillomatosis, health state utility weight of 0.69 over four years is assumed.
49 Disease specific utility weights
were multiplied to baseline age specific utility weights to estimate overall utility.
50
¶Cost per case is expressed in dollars at 2006 prices and represents average discounted lifetime costs of a new case of disease, including direct medical
costs such as cost of procedures, admissions to hospital, and visits to the doctor. Treatment costs of cervical cancer varied according to stage ($26 540 for
local, $28 430 for regional, $45 540 for distant) and included direct non-medical costs, such as patient time and transportation.
42
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cinating both sexes had a higher (less attractive) ratio,
ranging from $120000 per QALY (when including all
HPV 16 and HPV 18 related cancers at full efficacy) to
$350000 per QALY (when including only cervical
outcomes).
Impact of decreased vaccine efficacy in boys
To reflect uncertainty about vaccine efficacy in males
theanalyseswererepeatedinascenarioofvaccineeffi-
cacyloweredto75%inboys.Figure1indicatesthecost
effectiveness ratios associated with the strategies of
vaccinating girls alone and vaccinating both sexes in
the context of current screening with cytology (HPV
DNA testing for triage), when assuming 90% and
75% vaccine efficacy in boys. For this analysis,
HPV 6 and HPV 11 associated genital warts and all
health outcomes combined are also reported, includ-
ing HPV 6 and HPV 11 associated juvenile onset
recurrent respiratory papillomatosis. Lowering the
vaccine efficacy in males from 90% to 75% resulted in
higher (less attractive) cost effectiveness ratios asso-
ciated with inclusion of boys in the vaccination pro-
gramme. For example, when reflecting benefits
associated with cervical disease only, vaccinating
both sexes (compared with vaccinating girls alone)
increased from $290290 to $382860 per QALY as
vaccine efficacy decreased from 90% to 75% in boys.
When reflecting all health outcomes in women and
men, the ratio for a strategy of including boys was
$90870 per QALY assuming 90% vaccine efficacy
against all HPV 16, HPV 18, HPV 6, and HPV 11
related diseases in males; this ratio increased to
$123940 per QALY when vaccine efficacy was
decreased to 75%.
Impact of vaccination coverage, duration of protection, and
other uncertainties
When coverage for routine vaccination was assumed
toreachonly50%inbothsexes,thecostofvaccinating
boys remained more than $220000 per QALY when
only cervical outcomes were included; this ratio
decreasedto $62070 per QALYwhen efficacy against
all outcomes for both sexes was high and lifelong but
exceeded$92000whenefficacyagainstwartsinmales
and all non-cervical cancers was 50%. Duration of
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Impact of decreased HPV vaccine efficacy in boys on cost
effectiveness ratios. Height of bars indicates cost
effectiveness ratios associated with strategies of vaccinating
girls alone and with boys in the context of current cytology
screening (HPV DNA testing for triage), under two levels of
vaccine efficacy in boys: 90% against vaccine type disease
outcomes (85% against vaccine type HPV infections), and
75% against vaccine type infections and disease outcomes. In
both scenarios, vaccine efficacy of 100% against vaccine type
infections and disease outcomes in girls was assumed
Table 2 |Cost effectiveness of including boys in a vaccination programme against human papillomavirus (HPV) types 16 and 18 in the context of current
screening for cervical cancer*
Strategy†
Cancers in women only Cancers in both sexes
Cervical‡
Including other HPV 16
and HPV 18 cancers
(50% efficacy)§
Including other HPV 16
and HPV 18 cancers
(100% efficacy)¶
Including other HPV 16
and HPV 18 cancers
(50% efficacy)§
Including other HPV 16
and HPV 18 cancers
(90-100% efficacy)¶
Current screening using cytology
with HPV DNA testing for triage:
No vaccination+screening —— — — —
Vaccination of girls aged 12+screening 40 310 31 530 25 680 27 370 20 990
Vaccination of girls and boys aged 12+screening 290 290 242 520 208 110 164 580 114 510
Current screening using cytology with HPV DNA
testing for triage until age 30, then combined
cytology and HPV DNA testing after age 30:
No vaccination+screening —— — — —
Vaccination of girls aged 12+screening 42 450 30 370 23 310 25 270 18 130
Vaccination of girls and boys aged 12+screening 350 040 281 170 234 760 179 510 120 300
*Values represent incremental cost effectiveness ratios (additional cost divided by additional health benefit compared with next less costly strategy) expressed as cost ($) per quality
adjusted life year (QALY). Costs expressed in 2006 dollars.
†Separate analyses were done under different scenarios of screening. Competing strategies within each scenario vary by vaccination (no vaccination, vaccination of 12 year old girls only,
vaccination of 12 year old girls and boys at 75% coverage). Current screening assumes 53% of women are screened annually, 17% every two years, 11% every three years, 15% every five
years, and 5% are never screened.
‡Includes outcomes related to cervical disease only and assumes 100% lifelong vaccine efficacy against HPV 16 and HPV 18 related cervical disease.
§Includes outcomes related to cervical disease and other HPV 16 and HPV 18 related cancers (vulvar and vaginal cancers for women; penile cancer for men; and anal, oral, and
oropharyngeal cancers for both sexes) and assumes 50% lifelong vaccine efficacy against HPV 16 and HPV 18 related non-cervical cancers and 100% lifelong efficacy against HPV 16 and
HPV 18 related cervical disease.
¶Includes outcomes related to cervical disease and other HPV 16 and HPV 18 related cancers and assumes 100% lifelong vaccine efficacy against HPV 16 and HPV 18 related cancers in
women and 90% lifelong vaccine efficacy against HPV 16 and HPV 18 related cancers in men.
RESEARCH
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cination strategies, resulting in high cost effectiveness
ratios even when including all HPV related outcomes.
When vaccine induced immunity waned completely
after20years,thecosteffectivenessratioofvaccinating
girls alone was over $120000 per QALY compared
with current screening practice, and vaccinating both
sexes cost over $350000 per QALY.
Whenthecostpervaccinatedindividualwaslowered
to$360(includingthreedoses,supplies,administration,
patient time, and transportation; implying a cost per
dose of roughly $87), the cost of vaccinating both
sexes decreased to $63000 per QALY under an
assumption of high efficacy against all outcomes; this
improvement was attenuated when efficacy against
wartsinmalesandallnon-cervicalcancerswasassumed
tobe50%,althoughtheratioremainedbelow$100000
per QALY. When the cost per vaccinated individual
was increased to $600, the cost of vaccinating both
sexes exceeded $110000 per QALY, even under
favourable assumptions of high, lifelong vaccine effi-
cacy against all conditions. Potential cross protective
effects of the vaccine on infections and cervical disease
relatedtooncogenicHPVtypesotherthanHPV16and
HPV18hadonlyamodestimpactonthecosteffective-
nessratios,andevenusingourupperboundestimatefor
cross protection, vaccination of both sexes remained
well over $250000 per QALY when only cervical out-
comes were included. Varying costs associated with
screening and treatment for cervical cancer also had
minimal impact on the overall results.
Cost effectiveness of HPV vaccination and screening
strategies
To reflect newly proposed algorithms for improving
secondary prevention of cervical cancer, an analysis
was carried out to evaluate different combinations of
vaccination and screening strategies. For screening we
included cytology (HPV DNA testing for triage) every
two or three years starting at age 25, with a switch to
combined cytology and HPV DNA testing at age 35
(table 3). In addition to our primary outcome of cervi-
cal disease, we reported the benefits for all possible
health conditions associated with HPV 6, HPV 11,
HPV16,andHPV18forwomenandmenundervary-
ing assumptions of vaccine efficacy.
Underbasecaseassumptionsof75%vaccinationcov-
erage and complete, lifelong vaccine efficacy against
cervical disease only, a strategy of vaccinating 12 year
old girls with screening every three years in adulthood
would cost $37940 per QALY compared with screen-
ingeverythreeyearswithoutvaccination,andwouldbe
less costly and more effective than a strategy of screen-
ing every two years without vaccination. Vaccinating
both sexes, as well as vaccinating girls alone in the con-
text of more frequent screening, were either not cost
effective or exceeded $190000 per QALY.
When other HPV related outcomes were taken into
consideration,inclusionofboysinthevaccinationpro-
gramme in the context of screening every three years
waslesscostlyandmoreeffectivethanvaccinatinggirls
alone with screening every two years, but cost over
$120000 per QALY when vaccine efficacy was 50%
against health outcomes associated with HPV 6, HPV
11, HPV 16, and HPV 18 (except for cervical disease
and warts in females) or was 75% in males only. When
we assumed lifelong vaccine efficacy of 100% for
females and 90% for males (best case scenario), vacci-
nating both sexes along with screening every three
years resulted in a decrease in cost per QALY to
$88930. The cost per QALY of vaccinating both
sexes along with screening every two years remained
more than $210000 over all assumptions of vaccine
efficacy against other HPV related conditions.
DISCUSSION
Our results suggest that if vaccine coverage and effi-
cacy are high among preadolescent girls (12 years),
Table 3 |Cost effectiveness of human papillomavirus (HPV) vaccination and revised screening strategies*
Strategy†
Cervical‡
(100% efficacy)
All HPV related conditions in women and men§
50% efficacy¶
75% efficacy**
(boys only)
90% efficacy††
(boys only)
No vaccination+screening every three years ——— —
Vaccination of girls aged 12+screening every three years 37 940 17 560 11 930 11 930
No vaccination+screening every two years Dominated Dominated Dominated Dominated
Vaccination of girls and boys aged 12+screening every three years Not cost effective 131 010 122 680 88 930
Vaccination of girls aged 12+screening every two years 190 780 Dominated Dominated Dominated
Vaccination of girls and boys aged 12+screening every two years 390 440 220 940 212 910 220 940
*Values represent incremental cost effectiveness ratios (additional cost divided by additional health benefit compared with next less costly strategy) expressed as cost ($) per quality
adjusted life year. Costs expressed in 2006 dollars. Strategies are listed in order of increasing costs; those that are “dominated” are more costly and less effective than another strategy;
those that are “not cost effective” are less cost effective (have higher cost effectiveness ratios) than a more costly strategy.
†Strategies vary by vaccination (no vaccination, vaccination of 12 year old girls alone, vaccination of 12 year old girls and boys at 75% coverage) and screening (every two or three years
using cytology with HPV DNA testing for triage starting at age 25, with a switch to combined cytology and HPV DNA testing at age 35).
‡Includes outcomes related to cervical disease only and assumes 100% lifelong vaccine efficacy against HPV 16 and HPV 18 related cervical disease.
§Includes outcomes related to cervical disease and other HPV 16 and HPV 18 related cancers, and HPV 6 and HPV 11 related genital warts and juvenile onset recurrent respiratory
papillomatosis among women and men.
¶Assumes 50% lifelong vaccine efficacy against HPV 16 and HPV 18 related non-cervical cancers, and HPV 6 and HPV 11 related genital warts among men and juvenile onset recurrent
respiratory papillomatosis, and 100% lifelong vaccine efficacy against HPV 16 and HPV 18 related cervical disease and HPV 6 and HPV 11 related genital warts among women.
**Assumes 75% lifelong vaccine efficacy against all vaccine type health conditions among men and 100% lifelong vaccine efficacy against all vaccine type health conditions among women.
††Assumes 90% lifelong vaccine efficacy against all vaccine type health conditions among men and 100% lifelong vaccine efficacy against all vaccine type health conditions among women.
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grammeisunlikelytoprovidegoodvalueforresources
comparedwithvaccinatinggirlsonly.Thisfindingwas
stable even when we included potential vaccine bene-
fits against other HPV related conditions among both
women and men and under different scenarios of
screening for cervical cancer. When we assumed
lower vaccine efficacy, waning immunity, or higher
vaccine costs, vaccination of boys consistently
exceeded $250000 per QALY when reflecting bene-
fits to cervical disease only and $100000 per QALY
when including other HPV related conditions. We
found that vaccinating both sexes fell below a willing-
ness to pay threshold of $100000 per QALY only
under scenarios of high, lifelong vaccine efficacy
against all HPV related conditions (including other
non-cervical cancers, genital warts, and juvenile onset
recurrent respiratory papillomatosis), or scenarios of
lower vaccine efficacy with lower coverage or lower
vaccine costs.
Our finding that the cost effectiveness ratio of vacci-
natingpreadolescentgirlsalonewasbelow$50000per
QALYwhenvaccineefficacywashighandlonglasting
issimilartotheresultsofpreviousanalyses.
13-22Offour
studies that evaluated the cost effectiveness of includ-
ing boys in an HPV vaccination programmein similar
settings, three drew consistent conclusions. Under
comparable base case assumptions, two of the
studies
1521 and our analysis found that vaccinating
boysinadditiontogirlswasunlikelytobecosteffective
compared with vaccinating girls alone. In contrast,
another study
18 reported that vaccination of girls and
boys along with a temporary catch-up programme for
both sexes to age 24 was less than $50000 per QALY.
Several important distinctions may contribute to the
disparate findings, including (but not limited to) the
following. Firstly, we incorporated recent data on effi-
cacy against vaccine type HPV infection and diseases
in males
2526 that were lower than assumed in previous
analyses, contributing to the less attractive cost effec-
tiveness ratio for vaccinating both sexes compared
with the earlier study.
18 Likewise, differences in
assumptions of screening test characteristics could
influence the relative performance of vaccination stra-
tegies;theanalysisintheearlierstudy
18assumedlower
cytology sensitivity for detecting cervical intra-
epithelial neoplasia, which favours the vaccination
strategies.Unliketheearlierstudy
18wedidnotinclude
diminished quality of life among women with a diag-
nosisofcervicalintraepithelialneoplasia;becausevac-
cination will effectively reduce the number of cases
(andthereforeavert qualityof lifedecrements ofcervi-
calintraepithelialneoplasiadiagnosedthroughscreen-
ing) exclusion of this assumption makes the
vaccination strategies look less favourable. Other dis-
tinctions across analyses, including model structures
and simulation techniques, assumptions of natural
immunity, vaccination coverage and costs, analytical
time horizon, and discounting rates, have been dis-
cussed in several review papers.
65-69
When different vaccination and screening strategies
were considered simultaneously, vaccinating preado-
lescent girls only along withcytology (HPV DNA test-
ingfor triage)everythreeyearsstartingatage25and a
switchtocombinedcytologyandHPVDNAtestingat
age35consistentlyhad a costeffectivenessratiobelow
$50000perQALY.Thisfinding,corroboratedbysev-
eral studies,
131617 shows the importance of re-evaluat-
ingnewscreeningtestsastheybecomeavailableinthe
context of refined algorithms for screening frequency,
starting age, and follow-up procedures in women after
vaccination. Moreover, changes in the distribution of
HPV genotypes after widespread vaccination may
have important implications for the performance of
screening tests, including the decreased positive pre-
dictive value of cytology testing.
63 Alternative screen-
ing strategies involving HPV DNA testing alone as a
primary screening test in older women (>35 years)
with cytology as a triage for abnormal test results,
look promising on the basis of preliminary clinical
data as well as modelling results
17 and should be
explored more thoroughly.
Limitations of the study
Limitationsofouranalysisthatarerelatedtouncertain-
ties of the clinical course of included health conditions
and vaccine properties in the long term have been
discussed.
12 Firstly, assumptions about sexual beha-
viour were simplified on the basis of large population
surveys; however, variables of the dynamic model
were calibrated to fit age specific prevalence of HPV
in the population, such that the implications of our
assumptions on sexual mixing were consistent with
empiricaldata.Secondly,individualsinthepopulation
are likely to benefit differentially from the vaccine. A
limitation of our analysis is that we only represented
heterosexualpartnershipsandthereforedidnotreflect
HPV transmission among men who have sex with
men, who face a high risk of anal cancer and may rea-
lise a greater benefit from HPV vaccination. Such an
analysis would require a more comprehensive model
thatincludesafullerrangeofsexualbehaviours,which
we acknowledge as an important priority for future
work. Thirdly, data on incidence, mortality, and qual-
ity of life associated with HPV related cancers other
thancervicalcancerarealsolimited.Weusedmultiple
modelstoleveragethedifferentlevelsofdataavailable
for each health condition, yet inconsistencies between
model types and complexities associated with model
linkage should be further explored. Fourthly, data on
vaccineefficacyarereportedprimarilyforfemalesand
include outcomes related only to HPV infections, pre-
cancerous lesions, and genital warts. Longer term data
on vaccine properties of both the bivalent and quadri-
valent vaccines will be important to incorporate when
available, to provide more accurate estimates of their
expected benefits and costs.
We purposefully bound the scope of this analysis to
anassessmentofthecosteffectivenessofroutinevacci-
nation in preadolescent girls and boys at an optimistic
coverage rate of 75%, on the basis of achievable
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adolescents.
5556 Acknowledging the uncertainty in the
ultimate achievable coverage, we included an analysis
of 50% coverage and found that the cost effectiveness
ratios for both vaccination strategies became more
attractive because of the increased opportunities for
benefits from herd immunity. The cost effectiveness
of adding boys to the vaccination programme, how-
ever, decreased below $75000 per QALY only if we
assumed that vaccine efficacy against other HPV
related outcomes for both females and males was
high and lifelong; it exceeded $90000 per QALY
under assumptions of lower efficacy and remained
above$200000perQALYwhenonlytheprimaryout-
come of cervical cancer was reflected. We also did not
consider temporary catch-up programmes, as we
thought that data were inadequate for important
assumptions that would be required, including rates
for catch-up coverage stratified by age and sexual his-
tory. Nonetheless, because of the higher coverage of
girls in a catch-up campaign and consequent dimin-
ished opportunity for herd immunity benefits from
vaccinating boys, we expect that vaccinating boys
wouldbeevenlessattractiveundercatch-upscenarios.
Although we did not include decrements in quality
oflifeassociatedwithdiagnosedprecancerouscervical
lesions, which would favourthe vaccination strategies,
we also did not incorporate diminished quality of life
due to potential adverse events associated with vacci-
nation, which would favour the screening strategies.
To date causal links between the vaccine and serious
side effects have been inconclusive, although a recent
analysis using data from the US vaccine adverse event
reporting system suggested higher rates of venous
thromboembolic events and syncope among those
who received the HPV vaccine.
5170 Even minor side
effects cause undue health and economic burden and
may, in aggregate, outweigh the benefits of HPV vac-
cination since the population risk of cervical cancer—
and other HPV related conditions—in the United
States is low.
71 Inclusion of adverse events, and the
cost of surveillance or reporting of adverse events,
although likely to strengthen our results, is an impor-
tant priority to revisit as data become available.
Ouranalysisdoesnotaddressdecisionmakingatthe
individual level; indeed, families considering HPV
vaccination for boys, and who are willing to pay for
the vaccine, may consider the benefits of the vaccine
worthwhileintermsofreducingthefutureriskofgeni-
tal warts and possiblyother healthconditions.Instead,
weemphasisethepublichealthperspectiveofthisana-
lysis, whichhasthe objective ofinforminggeneralpol-
icyrecommendationsatthepopulationlevel,enabling
us to compare its value with other public health inter-
ventionsvyingforsimilarresources.Suchananalysisis
particularlyrelevantinthelightoftherecentprioritisa-
tion of “comparative effectiveness” research under the
American Recovery and Reinvestment Act of 2009.
72
Conclusions
Giventheinformationcurrentlyavailable,ouranalysis
favours HPV vaccination of preadolescent girls (with
continued screening in adulthood) as a valuable inter-
vention forits cost, consistentwith findingsfrom other
cost effectiveness studies.
13-22 Including boys in the
vaccinationprogramme,however,generallyexceeded
conventional thresholds of good value for money,
even under favourable conditions of vaccine protec-
tion and health benefits. Uncertainty still exists in
many areas that can either strengthen or attenuate
our findings. As new data become available and new
information emerges, assumptions and analyses will
need to be iteratively revised to continue to inform
policies on HPV vaccination.
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